Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Purchased by Foundations Investment Advisors LLC

Key Points

• Foundations Investment Advisors LLC increased its stake in Intuitive Surgical by 3,012.3% in the first quarter, acquiring an additional 34,943 shares to hold a total of 36,103 shares valued at $17.88 million.
• Intuitive Surgical reported a 21.4% year-over-year revenue growth in its latest quarter, with earnings per share of $2.19, surpassing analyst estimates.
• Several analysts recently adjusted their price targets for Intuitive Surgical, with Evercore ISI raising its target from $470 to $550, while Citigroup set a target of $650.

Foundations Investment Advisors LLC lifted its position in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 3,012.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 36,103 shares of the medical equipment provider's stock after acquiring an additional 34,943 shares during the quarter. Foundations Investment Advisors LLC's holdings in Intuitive Surgical were worth $17,881,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in ISRG. Chilton Capital Management LLC increased its position in Intuitive Surgical by 614.3% during the 1st quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 43 shares during the period. Parvin Asset Management LLC purchased a new stake in Intuitive Surgical during the 4th quarter worth approximately $26,000. Global Financial Private Client LLC grew its position in Intuitive Surgical by 253.3% during the 1st quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock worth $26,000 after purchasing an additional 38 shares during the last quarter. Elite Financial Inc. purchased a new stake in Intuitive Surgical during the 1st quarter worth approximately $26,000. Finally, Hurley Capital LLC acquired a new stake in Intuitive Surgical during the 4th quarter valued at approximately $28,000. Institutional investors own 83.64% of the company's stock.

Insider Buying and Selling

In related news, EVP Myriam Curet sold 4,500 shares of the business's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $492.48, for a total value of $2,216,160.00. Following the sale, the executive vice president directly owned 353 shares in the company, valued at $173,845.44. The trade was a 92.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Mark Brosius sold 216 shares of the business's stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $563.11, for a total transaction of $121,631.76. Following the completion of the transaction, the senior vice president directly owned 907 shares of the company's stock, valued at $510,740.77. The trade was a 19.23% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 7,610 shares of company stock worth $3,858,340 in the last three months. Corporate insiders own 0.70% of the company's stock.

Intuitive Surgical Stock Down 0.4%

NASDAQ:ISRG traded down $1.91 during midday trading on Monday, reaching $493.95. The stock had a trading volume of 2,472,156 shares, compared to its average volume of 1,835,437. The firm has a fifty day simple moving average of $528.51 and a two-hundred day simple moving average of $534.63. Intuitive Surgical, Inc. has a 12-month low of $425.00 and a 12-month high of $616.00. The stock has a market cap of $177.07 billion, a P/E ratio of 68.89, a P/E/G ratio of 5.20 and a beta of 1.64.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 EPS for the quarter, topping the consensus estimate of $1.93 by $0.26. The company had revenue of $2.44 billion for the quarter, compared to analyst estimates of $2.35 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The business's revenue was up 21.4% on a year-over-year basis. During the same period in the previous year, the firm earned $1.78 EPS. On average, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Piper Sandler reiterated an "overweight" rating and issued a $595.00 target price (up from $575.00) on shares of Intuitive Surgical in a research note on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft lowered Intuitive Surgical from a "hold" rating to a "sell" rating and decreased their price target for the company from $515.00 to $440.00 in a research note on Monday, June 9th. Wells Fargo & Company increased their target price on shares of Intuitive Surgical from $559.00 to $599.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 23rd. BTIG Research increased their price target on shares of Intuitive Surgical from $566.00 to $571.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. Finally, Evercore ISI raised their target price on shares of Intuitive Surgical from $470.00 to $550.00 and gave the company an "in-line" rating in a report on Tuesday, July 8th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $592.05.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.